Product Overview
[Drug Name]
Generic Name: Telmisartan Capsules
Trade Name: Liyu Telmisartan Capsules 40mg x 56 capsules
Pinyin Code: LiYu TiMiShaTanJiaoNang 40mg x 56Li
[Main Ingredient]
4-[(2-n-propyl-4-methyl-6-(1-methylbenzimidazol-2-yl)-benzimidazol-1-yl)methyl]diphenyl-2-carboxylic acid = Telmisartan.
[Properties]
This product is a capsule containing white or off-white granules or powder.
[Indications/Main Functions]
For the treatment of essential hypertension.
[Specifications]
40mg x 56 capsules
[Dosage and Administration]
Adults: 40mg-80mg once daily. Dosage is not affected by diet. No dosage adjustment is required for patients with mild to moderate renal impairment or the elderly. For patients with mild or moderate hepatic impairment, the dose of this product should not exceed 40 mg/day. For children: Safety and efficacy data for this product have not been established.
[Adverse Reactions]
Diarrhea and angioedema. These are mostly mild and transient, generally not requiring discontinuation of treatment. Their occurrence is not dose-related.
[Contraindications]
1. Telmisartan capsules are contraindicated in patients with biliary obstructive disease and severe hepatic or renal insufficiency. 2. Telmisartan capsules are contraindicated in pregnant and breastfeeding women.
[Drug Interactions]
1. Lithium: Concomitant use of lithium with angiotensin-converting enzyme inhibitors can cause reversible increases in blood lithium levels and toxic reactions. There have also been isolated cases of this condition caused by the concomitant use of lithium with angiotensin I receptor antagonists. Therefore, caution should be exercised when using lithium with this product. If combined use is necessary, blood lithium levels should be monitored during coadministration. 2. Some drugs can affect serum potassium levels or cause hyperkalemia (such as ACE inhibitors, potassium-sparing diuretics, potassium supplements, potassium-containing salt substitutes, cyclosporine A, or other drugs such as heparin sodium). If this product is used concomitantly with these drugs, it is recommended to monitor serum potassium levels. Based on experience with other drugs that affect the renin-angiotensin system, concomitant use of this product with these drugs may increase serum potassium levels (see Precautions). 3. Pharmacokinetic studies have investigated the interaction of this product with digoxin, warfarin, hydrochlorothiazide, glyburide, ibuprofen, paracetamol, amlodipine, and other drugs. Digoxin plasma concentrations may increase by 20% (in some cases by 39%), so clinical monitoring of digoxin plasma concentrations is necessary. 4. This product may enhance the antihypertensive effect of other antihypertensive drugs. Other clinically significant interactions have not been demonstrated. 5. Based on their pharmacological properties, the following drugs may enhance the antihypertensive effect of antihypertensive drugs, including telmisartan: baclofen and amifostine. In addition, alcohol, barbiturates, sedatives, hypnotics, or antidepressants may potentiate the effects of postural hypotension. 6. When used concomitantly with telmisartan, the Cmax of simvastatin metabolites (simvastatin acid) is slightly increased (1.34-fold) and its elimination is accelerated.
[Precautions]
1. If symptomatic hypotension occurs in the event of an overdose, supportive treatment should be initiated. Telmisartan capsules cannot be removed by hemodialysis. 2. This product may enhance the hypotensive effect of antihypertensive medications. 3. Serum lithium levels should be monitored when used concomitantly with certain medications. 4. No dosage adjustment is required for patients with mild to moderate renal impairment. The daily dose for patients with mild to moderate hepatic impairment should not exceed 40 mg. 5. This product is contraindicated in pregnant and breastfeeding women. 6. The safety of this product in pediatric patients has not been established; use with caution in children.
